CFZ533A
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $931,732 | 38 | 0 |
| 2019 | $238,391 | 13 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 51 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PARTIALLY-BLINDED, ACTIVE-CONTROLLED, MULTICENTER, RANDOMIZED STUDY EVALUATING EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) OF AN ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533, IN DE NOVO AND MAINTENANCE KIDNEY TRANSPLANT RECIPI | Novartis Pharmaceuticals Corporation | $700,401 | 0 |
| A 12-MONTH, OPEN-LABEL, MULTICENTER, RANDOMIZED, SAFETY, EFFICACY, PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) STUDY OF TWO REGIMENS OF ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533 VS. STANDARD OF CARE CONTROL, IN ADULT DE NOVO LIVER TRANSPLANT RECIPIENTS WITH | Novartis Pharmaceuticals Corporation | $274,500 | 0 |
| A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipi | Novartis Pharmaceuticals Corporation | $126,279 | 0 |
| A PARTIALLY-BLINDED, ACTIVE-CONTROLLED, MULTICENTER, RANDOMIZED STUDY EVALUATING EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) OF AN ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533, IN DE NOVO AND MAINTENANCE KIDNEY TRANSPLANT RECIPI | NOVARTIS PHARMACEUTICALS CORPORATION | $68,943 | 0 |
Top Doctors Receiving Payments for CFZ533A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $1.2M | 51 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 0
- Transactions 51
About CFZ533A
CFZ533A is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 51 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2019 to 2020. In 2020, $931,732 was paid across 38 transactions to 0 doctors.
The most common payment nature for CFZ533A is "Unspecified" ($1.2M, 100.0% of total).
CFZ533A is associated with 4 research studies, including "A PARTIALLY-BLINDED, ACTIVE-CONTROLLED, MULTICENTER, RANDOMIZED STUDY EVALUATING EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) OF AN ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533, IN DE NOVO AND MAINTENANCE KIDNEY TRANSPLANT RECIPI" ($700,401).